13 Results for "

Delta variant

" in MedChemExpress (MCE) Product Catalog:
Products (13)

13 Results for "Delta variant" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-N1943
CAS No.: 981-15-7
Synonyms: Δ13-Dehydrochaparrinone
Ailanthone (Δ13-Dehydrochaparrinone) is a potent inhibitor of both full-length androgen receptor (AR) (IC50=69 nM) and constitutively active truncated AR splice variants (AR1-651 IC50=309 nM).
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99341
CAS No.: 2415933-42-3
Synonyms: REGN10933

Target:  

SARS-CoV

Research Areas:  

Infection

Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms .
loading...
    loading...
Cat. No.: HY-149535
CAS No.: 2921711-74-0
Purity:  99.84%
Synonyms: WU-04
Target:  

SARS-CoV

Research Areas:  

Infection

Iscartrelvir (WU-04) is a non-covalent inhibitor of SARS-CoV-2, targeting the 3CLpro protein. Iscartrelvir has high inhibitory effect on the 3CLpro protein of 6 SARS-CoV-2 variants (Alpha, Beta, Gamma, Delta, Lambda and Omicron) and 2 coronaviruses (SARS-CoV and MERS-CoV) .
loading...
    loading...
Cat. No.: HY-P99346
CAS No.: 2444308-95-4
Synonyms: CT-P59

Research Areas:  

Infection

Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .
loading...
    loading...
Cat. No.: HY-174385
Target:  

SARS-CoV

Research Areas:  

Infection

SARS-CoV-2-IN-114 (Compound 36) is an antiviral agent. SARS-CoV-2-IN-114 exhibits significant antiviral activity against both the SARS-CoV-2 original strain and the Delta variant. SARS-CoV-2-IN-114 has an EC50 of 0.29 μM for inhibiting CPE of the SARS-CoV-2 original strain, and that for the Delta variant is 5.77 μM. SARS-CoV-2-IN-114 has low cytotoxicity and can be used in coronavirus research .
loading...
    loading...
Cat. No.: HY-151265
CAS No.: 2719679-31-7
Target:  

SARS-CoV

Research Areas:  

Infection

MMT5-14 is a remdesivir analogue with a higher antiviral activity in four variants of SARS-CoV-2 than Remdesivir (HY-104077). MMT5-14 inhibits SARS-CoV-2, α, β, γ and δ variants with EC50s of 0.4, 2.5, 15.9, 1.7 and 5.6 μM, respectively. MMT5-14 can be used for the research of COVID-19 .
loading...
    loading...
Cat. No.: HY-178291
CAS No.: 104959-32-2
Target:  

SARS-CoV

Research Areas:  

Infection

2-Chloro-2′-deoxyadenosine monophosphate is an anticoronavirus agent. It exhibits significant inhibitory effects against wild-type novel coronavirus, novel coronavirus variants (Beta, Delta, and Omicron strains), and other coronaviruses such as human coronavirus 229E, human coronavirus OC43, human coronavirus NL63, and mouse coronavirus MHV .
loading...
    loading...
Cat. No.: HY-168917
CAS No.: 149934-19-0
Synonyms: 9-AMN
Target:  

SARS-CoV Virus Protease

Research Areas:  

Infection

9-Aminominocycline (9-AMN) is the inhibitor for SARS-CoV-2 papain-like protease (SARS-CoV-2 PLpro), inhibits its deubiquitination (DUB) activity and protease activity with IC50 of 4.55 µM and 4.15 µM. 9-Aminominocycline inhibits the SARS-CoV variants Delta and Omicron replication in Calu-3 cell with IC50 of 1.04 µM and 2.35 µM .
loading...
    loading...
Cat. No.: HY-163913
Target:  

SARS-CoV

Research Areas:  

Infection

SARS-CoV-IN-5 (compound 49) is a highly selective, nonpeptidic and noncovalent 3CL pro inhibitor with IC50s of 38 nM, 21.1 nM and 86 nM for 3CL pro of SARS-CoV-1, SARS-CoV-2, Bat coronavirus WIV1, respectively. SARS-CoV-IN-5 inhibits the replication of the SARS-CoV-2 delta variant with an EC50 of 0.272 μM. SARS-CoV-IN-5 significantly reduces the lung viral copies in a K18-hACE2 transgenic mouse model. SARS-CoV-IN-5 has good target-specific and potential broad-spectrum anticoronavirus activities against SARS-CoV-1, WIV1, MERS, HCoV-OC43, HCoV-229E, and HKU9 .
loading...
    loading...
Cat. No.: HY-182894
Target:  

Virus Protease SARS-CoV

Research Areas:  

Infection

MR1-114 is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor with an IC50 of 0.037 μM. As a broad-spectrum inhibitor, MR1-114 maintains submicromolar activity against SARS-CoV-2 Delta, Omicron B.1.1.529 and Omicron BA.5 variants, with EC50 values of 0.18 μM, 0.39 μM and 0.20 μM, respectively. MR1-114 can be used for the research of coronavirus disease 2019 (SARS-CoV-2 infection) .
loading...
    loading...
Cat. No.: HY-P72069
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: ABC 29; ABC29; ABCC 1; ABCC; Abcc1; ATP binding cassette sub family C CFTR/MRP; member 1; ATP binding cassette sub-family C member 1; ATP binding cassette subfamily C member 1; ATP binding cassette transporter variant ABCC1Delta ex13; ATP binding cassette transporter variant ABCC1Delta ex13&14; ATP binding cassette transporter variant ABCC1Delta ex25; ATP binding cassette transporter variant ABCC1Delta ex25&26; ATP binding cassette, sub-family C CFTR/MRP; , member 1; ATP-binding cassette sub-family C member 1; DKFZp686N04233; DKFZp781G125; GS X; GSX; Leukotriene C4; transporter; LTC4 transporter; MRP 1; MRP; MRP1; MRP1_HUMAN; Multidrug resistance associated protein 1; Multidrug resistance protein; Multidrug resistance-associated protein 1; Multiple drug resistance associated protein; Multiple drug resistance protein 1
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-181661
Target:  

SARS-CoV Virus Protease

Research Areas:  

Infection

YL1004 is a potent, selective and orally active noncovalent inhibitor of SARS-CoV-2 papain-like protease (PL pro). YL1004 shows an IC50 of 17.5 nM and a Ki of 2.3 nM against PL pro, with an in vitro anti-SARS-CoV-2 EC50 of 0.08 μM-1.37 μM. YL1004 suppresses the proteolytic activity of PL pro and blocks its deubiquitinating and deISGylating effects to restore host innate antiviral immune signaling. YL1004 inhibits the replication of wild-type, Delta, Omicron variants and nirmatrelvir-resistant strains of SARS-CoV-2. YL1004 can be used for the research of COVID-19 (SARS-CoV-2 infection) .
loading...
    loading...
Cat. No.: HY-175829
Target:  

SARS-CoV

Research Areas:  

Infection

SARS-CoV-2-IN-119 (Compound A28) is a SARS-CoV-2 fusion inhibitor. SARS-CoV-2-IN-119 strongly inhibits Omicron entry with an EC50s of 1.95  and 1.08 μM for pOmicron (BA.2.86.1) and wild Omicron. SARS-CoV-2-IN-119 also has antiviral activities against wild SARS-CoV-2 and other variants, such as pseudotyped Delta SARS-CoV-2, pOmicron (BA.4) and (KP.3). SARS-CoV-2-IN-119 directly interferes with Omicron S2-mediated viral membrane fusion to block Omicron virus into host cells. SARS-CoV-2-IN-119 can be used for COVID-19 research .
loading...
    loading...
  • 1